UCB S.A. UNSP.ADR 1/2 Market Cap ($44.84 Billion)
Market Cap & Net Worth: UCB S.A. UNSP.ADR 1/2 (UNC0)
UCB S.A. UNSP.ADR 1/2 market cap. UCB S.A. UNSP.ADR 1/2 (F:UNC0) has a market capitalization of $44.84 Billion (€38.35 Billion) as of October 31, 2026. Listed on the F stock exchange, this Germany-based company holds position #599 globally and #124 in its home market, demonstrating a -11.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying UCB S.A. UNSP.ADR 1/2's stock price €120.00 by its total outstanding shares 379992422 (379.99 Million).
UCB S.A. UNSP.ADR 1/2 Market Cap History (2021–2026)
UCB S.A. UNSP.ADR 1/2 market cap history from 2021 to 2026. Data shows growth from $20.88 Billion to $61.75 Billion (25.98% CAGR). Check UNC0 stock price for real-time trading data and today's change.
UCB S.A. UNSP.ADR 1/2 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how UCB S.A. UNSP.ADR 1/2's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see UCB S.A. UNSP.ADR 1/2 cash conversion from operations for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
6.71x
UCB S.A. UNSP.ADR 1/2's market cap is 6.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
33.36x
UCB S.A. UNSP.ADR 1/2's market cap is 33.36 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $20.88 Billion | $5.78 Billion | $1.06 Billion | 3.61x | 19.73x |
| 2022 | $15.69 Billion | $5.52 Billion | $418.00 Million | 2.84x | 37.54x |
| 2023 | $16.67 Billion | $5.25 Billion | $343.00 Million | 3.17x | 48.61x |
| 2024 | $41.98 Billion | $6.15 Billion | $1.06 Billion | 6.82x | 39.42x |
| 2025 | $51.98 Billion | $7.74 Billion | $1.56 Billion | 6.71x | 33.36x |
Competitor Companies of UNC0 by Market Capitalization
Companies near UCB S.A. UNSP.ADR 1/2 in the global market cap rankings as of October 31, 2026. See UNC0 equity to assets ratio to understand what proportion of total assets are financed by equity.
Key companies related to UCB S.A. UNSP.ADR 1/2 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of UCB S.A. UNSP.ADR 1/2 (2021–2026)
Market capitalization of UCB S.A. UNSP.ADR 1/2 from 2021 to today. Between 2021 and today, UCB S.A. UNSP.ADR 1/2's market cap moved from $20.88 Billion to $ 61.75 Billion, with a yearly change of 25.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €61.75 Billion | +18.80% |
| 2025 | €51.98 Billion | +23.81% |
| 2024 | €41.98 Billion | +151.78% |
| 2023 | €16.67 Billion | +6.26% |
| 2022 | €15.69 Billion | -24.83% |
| 2021 | €20.88 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of UCB S.A. UNSP.ADR 1/2 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $44.84 Billion USD |
| MoneyControl | $44.84 Billion USD |
| MarketWatch | $44.84 Billion USD |
| marketcap.company | $44.84 Billion USD |
| Reuters | $44.84 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About UCB S.A. UNSP.ADR 1/2
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthr… Read more